SCHEMBL1970068

SCHEMBL1970068

O=C(COc1ccccc1)Nc1nc2[nH]cnc2c(=O)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
TP53 P04637 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 1/20 0.58
ALOX12 P18054 1/20 0.58
ALPL P05186 1/20 0.52
MAPT P10636 3/20 0.48
GAA P10253 1/20 0.48
ADORA3 P0DMS8 3/20 0.46
ADORA2A P29274 3/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
NOTUM Q6P988 1/20 0.43
THRB P10828 1/20 0.43
HPGD P15428 1/20 0.43
ADORA1 P30542 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17552159 0.85 TRPV1 (0.48) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL2623146 0.83 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1ALOX12KDM4E
SCHEMBL1970070 0.82 GDA (0.58) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL6937511 0.82 KMT2A (0.47) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL3236094 0.82 ALOX15 (0.58) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL1425017 0.79 ADORA2A (0.52) NPC1RAB9ATP53SMN1; SMN2MAPT
SCHEMBL12227604 0.78 GDA (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL28472801 0.78 ROCK2 (0.47) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL25921184 0.77 GAA (0.56) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL30208590 0.76 TERT (0.38) NPC1RAB9ATP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-05-14 US claimed
US-20160340382-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-11-24 US claimed
EP-2334692-B1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS UNIV MCGILL (CA) 2016-04-13 EP claimed
US-9249175-B2 RNA monomers containing O-acetal levulinyl ester groups and their use in RNA microarrays THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-02-02 US claimed
US-20120178638-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-07-12 US claimed
EP-2334692-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS The Royal Institution for the Advancement of Learning / McGill University (CA) 2011-06-22 EP claimed
WO-2010025566-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2010-03-11 WO claimed
EP-2862868-B1 INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME DAIICHI SANKYO CO LTD (JP) 2020-04-08 EP disclosed
US-9738681-B2 Intermediate for production of nucleoside analog and method for producing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-08-22 US disclosed
US-20160068561-A9 Intermediate for Production of Nucleoside Analog and Method for Producing the Same DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-10 US disclosed
US-20150152132-A1 Intermediate for Production of Nucleoside Analog and Method for Producing the Same DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
EP-2862868-A1 INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays EFTUD2, RNMT, NSUN2 NPC1 4871/4885RAB9A 4371/4885TP53 2717/4885
US-20150152132-A1 Intermediate for Production of Nucleoside Analog and Method for Producing the Same RNGTT, NSUN2, RNMT NPC1 1755/4885RAB9A 3756/4885TP53 2864/4885
US-20160068561-A9 Intermediate for Production of Nucleoside Analog and Method for Producing the Same RNGTT, NSUN2, RNMT NPC1 1755/4885RAB9A 3756/4885TP53 2864/4885
US-20160340382-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS EFTUD2, RNMT, RNGTT NPC1 4873/4885RAB9A 4368/4885TP53 2504/4885
US-20120178638-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS EFTUD2, RNMT, RNGTT NPC1 4873/4885RAB9A 4368/4885TP53 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.